Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
Filter News
Show All Results
News By Country
News By Tag
Nucleic Acids Remove


November 2014
Sa Fr Th We Tu Mo Su
22 21 20 19 18 17 16

nucleic acids Press Releases

  + XML/RSS  



By MoBiTec GmbH
Nucleases are nucleic acid degrading enzymes capable of cleaving the phosphodiester bonds between the nucleotide subunits of its substrate. HS-Nuclease, a broad band nuclease, is an indispensable tool to reduce the viscosity of cell lysates.

By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.

By Mary Ann Liebert, Inc., publishers
Drugs comprised of single strands of DNA, called aptamers, can bind to targets inside tumor cells causing cell death. But these DNA drugs cannot readily get inside tumor cells on their own.

By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.

By TriLink BioTechnologies, Inc.
TriLink BioTechnologies, Inc. was awarded a Phase I SBIR Grant by the National Institutes of Health to develop an approach to RNA sample preparation for Next Generation Sequencing (NGS) using TriLink's expertise in nucleic acid chemistry.

By Mary Ann Liebert, Inc., publishers
By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease.

All Press Releases

By MoBiTec GmbH
Nucleases are nucleic acid degrading enzymes capable of cleaving the phosphodiester bonds between the nucleotide subunits of its substrate. HS-Nuclease, a broad band nuclease, is an indispensable tool to reduce the viscosity of cell lysates.

By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.

By Mary Ann Liebert, Inc., publishers
Drugs comprised of single strands of DNA, called aptamers, can bind to targets inside tumor cells causing cell death. But these DNA drugs cannot readily get inside tumor cells on their own.

By Mary Ann Liebert, Inc., publishers
Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext.

By TriLink BioTechnologies, Inc.
Dr. Gerald Zon, noted scientist in the field of nucleic acid research launched a new blog in conjunction with TriLink Biotechnologies. The blog, Zone In with Zon (zon.trilinkbiotech.com), focuses on what's trending in the field of nucleic acids.

By TriLink BioTechnologies, Inc.
TriLink BioTechnologies, Inc. was awarded a Phase I SBIR Grant by the National Institutes of Health to develop an approach to RNA sample preparation for Next Generation Sequencing (NGS) using TriLink's expertise in nucleic acid chemistry.

By Mary Ann Liebert, Inc., publishers
By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease.

By Mary Ann Liebert, Inc., publishers
A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells.

By MarketResearch.com
Molecular diagnostics (MDx) is the fastest growing segment of the in vitro diagnostics industry (IVD).



Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share